These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15010011)

  • 1. The tissue renin-angiotensin-aldosterone system in diabetes mellitus.
    Hanes DS; Nahar A; Weir MR
    Curr Hypertens Rep; 2004 Apr; 6(2):98-105. PubMed ID: 15010011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II (AT(1)) receptor antagonists, diabetes, and nephropathy: do differences between the renal and systemic circulations explain the outcomes observed with ARBs and ACE inhibitors?
    Giles TD; Sander GE
    Am J Geriatr Cardiol; 2002; 11(1):62-5. PubMed ID: 11773721
    [No Abstract]   [Full Text] [Related]  

  • 4. Blockade of the renin-angiotensin system.
    Cheung BM
    Hong Kong Med J; 2002 Jun; 8(3):185-91. PubMed ID: 12055364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system and cardiovascular risk.
    Schmieder RE; Hilgers KF; Schlaich MP; Schmidt BM
    Lancet; 2007 Apr; 369(9568):1208-19. PubMed ID: 17416265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J; Praga M; de Vinuesa SG
    Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II and its receptors in the diabetic kidney.
    Burns KD
    Am J Kidney Dis; 2000 Sep; 36(3):449-67. PubMed ID: 10977776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
    Kalantarinia K; Okusa MD
    Curr Diab Rep; 2006 Feb; 6(1):8-16. PubMed ID: 16522275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M; Zanchi A
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations.
    Gilbert RE; Krum H; Wilkinson-Berka J; Kelly DJ
    Diabet Med; 2003 Aug; 20(8):607-21. PubMed ID: 12873287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC; MacDonald TM
    Int J Clin Pract; 1998 Oct; 52(7):475-81. PubMed ID: 10622089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
    Schunkert H
    MMW Fortschr Med; 2004 Jun; 146(23):60. PubMed ID: 15373137
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypertension and diabetes: role of the renin-angiotensin system.
    Jandeleit-Dahm K; Cooper ME
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):469-90, vii. PubMed ID: 16959581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of angiotensin blockade in the management of cardiovascular disease.
    Nantel P; René de Cotret P
    Can J Cardiol; 2010 Dec; 26 Suppl E():7E-13E. PubMed ID: 21620285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders.
    Stanton A
    Am J Cardiovasc Drugs; 2003; 3(6):389-94. PubMed ID: 14728059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.